Phase IIb trial

Related by string. Phase IIb trials * phase . phases . Phases . PHASE : Phase III clinical trials . Phase III trials . Phase III clinical . Phase 2b clinical / IIB . IIBS : Phase IIb clinical . Phase IIb . initiate Phase IIb . Phase IIb clinical trials / trialed . trialing . trials . Trial : Week Premium Trial . randomized controlled trial . randomized controlled trials . placebo controlled clinical trials * *

Related by context. All words. (Click for frequent words.) 81 Phase 2b trial 81 Phase IIb 80 Phase 2b study 80 phase IIb 79 Phase III clinical 79 Phase IIb clinical 78 Phase III trials 78 Phase Ib 78 Phase IIa trial 78 Phase 2a trial 78 Phase IIa 77 Phase III 77 Phase III clinical trials 77 Phase 2b clinical 77 Phase 2a clinical 76 phase IIb clinical 76 pivotal Phase III 76 phase IIa 75 Phase IIb trials 75 phase IIa clinical 75 Phase IIa clinical 74 clinical trial 74 Phase 2a 74 confirmatory Phase III 73 Phase 2b 73 phase IIb trial 73 Phase IIIb clinical 73 Phase Ib clinical 72 Phase 1b clinical 72 Phase 1b 71 Phase III pivotal 70 clinical trials 70 Phase 1b trial 70 Phase Ib study 70 phase 2a 70 Phase II 69 dose escalation trial 69 dose escalation Phase 68 placebo controlled clinical 68 Phase Ia 68 phase Ib 68 placebo controlled Phase 68 confirmatory Phase 3 68 Phase Ib II 68 multicenter Phase 68 placebo controlled 68 Phase 1a 68 multicenter Phase II 67 pivotal Phase 67 Phase IIa trials 67 registrational 67 Phase IIB 67 IIa trial 67 dose escalation study 67 registrational trial 67 multicenter clinical 67 Phase #b/#a 67 multiple ascending dose 66 randomized Phase III 66 dirucotide 66 SUCCEED trial 66 Phase 1a clinical 66 PRX # 66 phase IIb study 66 cannabinor 66 randomized placebo controlled 66 Phase IIb clinical trials 66 randomized Phase 66 JAK inhibitor 66 randomized Phase IIb 66 BRIM3 65 phase Ib clinical 65 clinical pharmacology studies 65 Phase 2b clinical trials 65 oral ridaforolimus 65 initiate Phase IIb 65 BAY #-# 65 double blind placebo 65 placebo controlled Phase III 65 blind randomized placebo 65 elotuzumab 65 ADVANCE PD 65 placebo controlled randomized 64 diabetic neuropathic pain 64 Corlux 64 Phase IIb III 64 GALNS 64 mipomersen 64 Amigal 64 forodesine 64 Phase Ib clinical trials 64 multicenter randomized placebo controlled 64 investigational compound 64 IIa clinical trial 64 alvespimycin 64 APEX PD 64 Mipomersen 64 pivotal bioequivalence 64 randomized controlled 64 Plicera 64 ocrelizumab 64 randomized clinical 64 multicenter 64 ENDEAVOR IV 63 dose escalation clinical 63 TG MV 63 AEGR 63 Phase IIIb 63 rALLy clinical trial 63 single ascending dose 63 double blinded placebo 63 INCB# [001] 63 CEQ# 63 dose escalation 63 European Sepsis Trial 63 Phase III randomized 63 TMC# C# 63 BRIM2 63 Amrubicin 63 Phase IIIb study 63 investigational drug 63 multicenter study 63 BCX# 63 IMGN# 63 Dacogen injection 63 ozarelix 63 PEG PAL 63 INCB# [002] 63 AQ4N 63 randomized double 63 Phase #b/#a trial 63 Laquinimod 63 PDE4 inhibitor 63 masked placebo controlled 63 Phase III randomized controlled 63 phase IIIb 63 oral deforolimus 62 Phase #b/#a clinical 62 Asentar 62 bicifadine 62 HGS# 62 fostamatinib 62 pertuzumab 62 dexanabinol 62 Fx #A 62 initiate Phase 2b 62 HuMax CD4 62 eniluracil 62 Fodosine 62 relapsing remitting multiple sclerosis 62 tremelimumab 62 incyclinide 62 denufosol 62 ATL# [001] 62 COMFORT II 62 NO# [002] 62 Pivotal Trial 62 blinded placebo controlled 62 pharmacokinetic studies 62 ruxolitinib 62 PRT# 62 lintuzumab 62 Phenoptin 62 AZILECT ® 62 Zenvia ™ 62 cetrorelix 62 Phase #/#a 62 RSD# oral 62 Zerenex 62 midstage trials 62 ANCHOR trial 62 deforolimus 62 axitinib 62 glufosfamide 62 multicenter prospective 62 BLA filing 62 relapsed refractory multiple myeloma 62 active comparator 62 Phase IIa clinical trials 62 randomized controlled Phase 62 IIa clinical 62 unblinding 62 IIb clinical trial 62 elagolix 62 brivaracetam 62 ganetespib 62 prospective randomized 62 HCV SPRINT 62 multicenter phase 61 metastatic hormone refractory 61 NGX# 61 multicentre randomized 61 BLA submission 61 opioid induced bowel dysfunction 61 Phase Ib IIa 61 IND enabling 61 PREOS 61 MBP# [001] 61 ADAGIO study 61 randomized multicenter 61 HuMax EGFr 61 blinded randomized placebo controlled 61 Zenvia Phase III 61 pharmacokinetic PK 61 selective androgen receptor modulator 61 midstage studies 61 teduglutide 61 dose cohorts 61 Alzhemed TM 61 randomized Phase 2b 61 ELACYT 61 budesonide foam 61 VEGF Trap 61 riociguat 61 TMC# [002] 61 RG# [001] 61 NDA submission 61 phase III ACCLAIM 61 Phase III placebo controlled 61 placebo controlled clinical trials 61 MIST II 61 AP# [003] 61 IMA# 61 MAA submission 61 PSN# [002] 61 octreotide implant 61 CRx 61 aflibercept 61 label dose escalation 61 SNT MC# 61 II Clinical Trial 61 KRN# 61 SinuNase 61 unblinded 61 PXD# 61 lomitapide 61 initiate Phase 1b 61 StaphVAX 61 investigational humanized monoclonal antibody 61 Phase III confirmatory 61 Phase 2b randomized 61 HuMax CD# 61 eltrombopag 61 cell lymphoma CTCL 60 CCR5 antagonist 60 HspE7 60 TELCYTA 60 Allovectin 7 ® 60 huC# DM4 60 sunitinib malate 60 CB2 selective receptor agonist 60 olaparib 60 refractory metastatic colorectal cancer 60 mertansine 60 HCV RESPOND 2 60 AeroLEF TM 60 PREOS R 60 TELINTRA 60 AZILECT R 60 FOLOTYN ® 60 blind randomized 60 AEG# 60 tanespimycin 60 unblind 60 Rezular 60 NP2 Enkephalin 60 valopicitabine 60 label multicenter 60 severe hypercholesterolemia 60 SAR# [004] 60 Allovectin 7 R 60 EndoTAG TM -1 60 Ozarelix 60 dosing cohorts 60 tolerability 60 oral prodrug 60 CHAMPION PCI 60 dose dose escalation 60 MAXY alpha 60 pharmacokinetic PK study 60 dyskinesia PD LID 60 Traficet EN 60 generation purine nucleoside 60 double blinded randomized 60 Aurora kinase inhibitor 60 preclinical 60 multicenter randomized double 60 LibiGel Phase III 60 receptor tyrosine kinase inhibitor 60 Desmoteplase 60 OncoVEX GM CSF 60 Pimavanserin 60 rALLy trial 60 Bronchitol 60 Bicifadine 60 methylnaltrexone 60 velafermin 60 Oglemilast 60 TBC# 60 IDX# 60 HGS ETR1 60 Diamyd ® 60 investigational oral 60 viral kinetic 60 MEND CABG 60 tivozanib 60 IND submission 60 lorvotuzumab mertansine 60 Phase 2b kidney transplant 60 RhuDex ® 60 histone deacetylase HDAC inhibitor 60 metastatic HRPC 60 ponatinib 60 PROSTVAC ® 60 PANVAC VF 60 Phase III Clinical Trial 60 MOZOBIL 60 mTOR inhibitor 60 PROMACTA 60 Quinamed 60 alvimopan 60 YONDELIS 60 multicenter placebo controlled 60 preclinical studies 60 EOquin 60 initiate Phase Ib 60 controlled multicenter 60 initiate Phase 60 zanolimumab 60 MERLIN TIMI 59 varespladib 59 ProSavin 59 ISIS # 59 oral methylnaltrexone 59 GetGoal Phase III 59 Phase 2a clinical trials 59 IL# PE#QQR 59 CoFactor 59 GAMMAGARD 59 Ostarine 59 CDP# 59 phase IIb III 59 multicenter randomized 59 Zelrix 59 Relovair 59 midstage study 59 enzastaurin 59 Urocidin 59 refractory CLL 59 alemtuzumab Campath 59 GLPG# 59 Allovectin 7 59 SYMMETRY trial 59 PFO migraine 59 vandetanib 59 blinatumomab 59 atrasentan 59 blind placebo controlled 59 Torisel 59 Phase IIb Trial 59 Board DSMB 59 IMC A# 59 albinterferon alfa 2b 59 AIR CF1 59 bendamustine 59 dose cohort 59 QLT# 59 MAGE A3 ASCI 59 VQD 59 prospective multicenter 59 lupus nephritis 59 talactoferrin 59 Cloretazine R VNP#M 59 Zalbin 59 ITAX 59 ASA# 59 daclizumab 59 Azixa 59 AZD# 59 tolevamer 59 sNDA submission 59 Tavocept 59 Phase 59 metastatic sarcomas 59 ALN TTR# 59 Ocrelizumab 59 prospective randomized controlled 59 reslizumab 59 AZX# 59 evaluating tivozanib 59 OvaRex ® MAb 59 ARRY 59 virus HCV protease inhibitor 59 CR# vcMMAE 59 obatoclax 59 Sym# 59 label multicenter Phase 59 vidofludimus 59 Icatibant 59 LymphoStat B 59 TOCOSOL Paclitaxel 59 Triolex 59 Initiate Phase 59 fidaxomicin Phase 3 59 sunitinib 59 Microplasmin 59 RDEA# 59 placebo controlled trials 59 entinostat 59 ataluren 59 multicenter Phase III 59 Cimzia ® certolizumab pegol 59 PRTX 59 integrase inhibitor 59 Ixempra 59 Factor VIIa 59 NUVIGIL 59 Pivotal Phase III 59 visilizumab 59 Elocalcitol 59 relapsed multiple myeloma 59 tezampanel 59 Nuvion 59 dexpramipexole 59 docetaxel Taxotere R 59 ABSORB trial 59 dirucotide MBP# 59 Phase III Trial 59 multicentre randomized double 59 EFAPROXYN 59 darusentan 59 zalutumumab 59 injectable formulation 59 Loramyc R 59 TEMSO 59 LUX Lung 59 huN# DM1 59 Ophena TM 59 antibody MAb 59 sorafenib Nexavar 59 Canvaxin 59 Lupuzor 59 ofatumumab 59 Memryte 59 IPL# 59 alogliptin 59 ketolide antibiotic 59 TLK# 59 RGB # 59 eprotirome 59 EOquin TM 59 EDEMA3 59 Aryplase 59 sapacitabine 59 Evoltra TM 59 Marqibo 59 CLIRS trial 59 PNP inhibitor 59 monotherapy 59 HCV protease inhibitor 59 omacetaxine mepesuccinate 59 GLP toxicology studies 59 EchoCRT 59 Tyrima 59 PS# [001] 59 Empatic 59 tezampanel NGX# 59 Menerba 59 dacetuzumab 59 TACI Ig 58 Phase IIb kidney transplant 58 confirmatory clinical 58 VNP#M 58 APPRAISE 58 laquinimod 58 NVA# 58 REVIVE Diabetes 58 T DM1 58 Augment Injectable 58 safinamide 58 midstage clinical trial 58 HPTN 58 PD LID 58 Cloretazine ® 58 Phase 1b clinical trials 58 pradefovir 58 Phase lll 58 iniparib 58 Azilect ® 58 Phase III Clinical Trials 58 SEPET TM 58 diarrhea predominant irritable 58 Sular formulation 58 hormone refractory prostate cancer 58 investigational pan BCR 58 eosinophilic asthma 58 Annamycin 58 JAK2 inhibitor 58 midstage clinical 58 CLL8 58 ENRICH trial 58 bardoxolone 58 maribavir 58 assessing T DM1 58 ularitide 58 Fibrillex TM 58 otelixizumab 58 subcutaneous formulation 58 edoxaban 58 Phase III Pivotal 58 generation PNP inhibitor 58 Genasense ® 58 Azedra 58 BRAF inhibitor 58 FOLOTYN 58 VITAL Trial 58 elacytarabine 58 initiate Phase IIa 58 teriflunomide 58 bortezomib Velcade 58 Oncoscience AG 58 cangrelor 58 AIM HIGH 58 tesmilifene 58 miconazole Lauriad ® 58 Ceflatonin 58 randomized multicentre 58 Cannabinor 58 torezolid phosphate 58 PRIMO CABG 58 Synavive 58 Genz # 58 Personalized Immunotherapy 58 Reverset 58 HuLuc# 58 Investigational Device Exemption IDE 58 neratinib 58 lintuzumab SGN 58 ascending dose 58 Viramidine 58 treatment naïve genotype 58 posaconazole 58 DSMB 58 PF # [001] 58 MGCD# [001] 58 oral formulation 58 randomized controlled clinical 58 Archexin 58 rasagiline 58 PEARL SC 58 TASKi2 58 apricitabine 58 MEK inhibitor 58 pralatrexate 58 voreloxin 58 CA4P 58 XIENCE V Stent System 58 RezularTM 58 Aurexis 58 randomized clinical trials 58 MNTX 58 ATryn R 58 ELND# 58 Shigamabs ® 58 darapladib 58 maraviroc 58 nalbuphine ER 58 Marketing Authorization Application 58 ofatumumab HuMax CD# 58 pomalidomide 58 eculizumab 58 Phase #/#a trial 58 cutaneous T cell 58 belinostat 58 ThermoDox R 58 Nexavar sorafenib 58 ganaxolone 58 ZYBRESTAT 58 subanalysis 58 trial evaluating PRX# 58 DDP# 58 dextromethorphan quinidine 58 apremilast 58 Iluvien 58 Viprinex 58 APEX AMI trial 58 ICA # 58 relapsing multiple sclerosis 58 Tocosol Paclitaxel 58 perifosine 58 ToGA 58 GSK# [002] 58 carfilzomib 58 relapsing remitting MS RRMS 58 Zolinza 58 subcutaneously administered 58 APTIVUS 58 Dyloject TM 58 SILENOR TM 58 polymerase inhibitor 58 clofarabine 58 Omigard 58 PRECiSE 58 angiogenesis inhibitor 58 IMC #B 58 GW# [003] 58 ADX# 58 refractory Hodgkin lymphoma 58 ILLUMINATE 58 symptomatic BPH 58 multicenter randomized Phase 58 Clolar ® 58 PEG Interferon lambda 58 Bezielle 58 painful diabetic neuropathy 58 AVADO 58 vascular disrupting agent 58 Telcyta 58 ulimorelin 58 arzoxifene 57 Proxinium TM 57 AIR CF2 57 interferon gamma 1b 57 Sulonex 57 Orazol 57 Dalbavancin 57 rNAPc2 57 R#/MEM # 57 cetuximab Erbitux 57 amrubicin 57 PRECISE Trial 57 PHX# 57 FTY# fingolimod 57 pazopanib 57 Diabetic Macular Edema 57 celgosivir 57 Cethromycin 57 Firazyr 57 pharmacodynamics 57 efficacy endpoint 57 randomized multicenter Phase III 57 Marketing Authorization Application MAA 57 FORTIS M trial 57 multicentre 57 Phase IIb Clinical Trial 57 rindopepimut 57 maximally tolerated dose 57 Phase 1b dose escalation 57 PTK ZK 57 MEND CABG II 57 Safinamide 57 trastuzumab emtansine T DM1 57 Phase III psoriasis 57 Enzastaurin 57 Onalta ™ 57 IIa trials 57 microplasmin 57 Denufosol 57 Vilazodone 57 Santhera 57 ThermoDox ® 57 NKTR 57 Lu AA# 57 bazedoxifene 57 randomized controlled multicenter 57 Dapagliflozin 57 DermaVir Patch 57 ABSORB clinical 57 goserelin 57 confirmatory Phase 57 GRN#L 57 IPLEX 57 Syncria 57 Plenaxis TM 57 bapineuzumab 57 LibiGel ® 57 prospective randomized placebo 57 RE LY ® 57 LCP AtorFen 57 lixisenatide 57 vosaroxin 57 trabedersen 57 lymphoma CTCL 57 Phase III VISTA 57 dimebon 57 Serdaxin 57 prospective observational 57 Insegia 57 Onrigin 57 nonclinical studies 57 RELOVAIR ™ 57 LEUKINE 57 LUMINATE 57 AGILECT R 57 pharmacokinetic 57 Aplidin 57 Cimzia TM 57 LEVADEX 57 liprotamase 57 iloperidone 57 LBH# 57 nab paclitaxel 57 Aflibercept 57 dalbavancin 57 Randomized Phase 57 tiapamil 57 Zavesca r 57 baminercept 57 orBec 57 HCV NS5B polymerase 57 temsirolimus 57 randomized blinded 57 ongoing Phase 1b 57 velaglucerase alfa 57 Androxal TM 57 treatment naive genotype 57 Troxatyl 57 Omacetaxine 57 candidates Dyloject TM 57 oxymorphone ER 57 JANUVIA 57 recurrent malignant glioma 57 PRE SURGE 57 RhuDex 57 Omnitarg 57 Sapacitabine 57 cetuximab Erbitux R 57 Phase III ALLEGRO 57 DU #b 57 avanafil 57 Targretin 57 SUTENT 57 bosutinib 57 neurogenic orthostatic hypotension 57 metaglidasen 57 romidepsin 57 Tamibarotene 57 Cetrorelix 57 INT# [002] 57 LymphoStat B TM 57 TRO# 57 stage IIIB 57 Xanafide 57 pegloticase 57 safety tolerability pharmacokinetics 57 Tarceva TM 57 Ceplene 57 Serada 57 MyVax R 57 metastatic renal cell 57 multicenter randomized controlled 57 Cloretazine 57 Luveniq 57 HGS ETR2 57 MAP# 57 immunomodulatory therapy 57 placebo controlled studies 57 non nucleoside inhibitor 57 DR Cysteamine 57 CUSTOM III 57 ACTEMRA TM 57 dose escalation phase 57 Phase III TRIST 57 MIRCERA 57 GRN# 57 Dextofisopam 57 Ceflatonin R 57 GV# [001] 57 compound INCB# 57 Nexavar ® 57 pitavastatin 57 Civacir 57 senicapoc 57 PROPEL trial 57 prospective multicenter randomized 57 ACTEMRA 57 CRLX# 57 vicriviroc 57 luliconazole 57 oral rivaroxaban 57 pharmacokinetics PK 57 VPRIV 57 mGluR5 NAM 57 NOX E# 57 multi kinase inhibitor 57 investigational 57 TASKi3 57 vilazodone 57 betrixaban 57 CCX# 57 safety tolerability 57 Pivotal Phase 57 prucalopride 57 JAK1 57 PRECISE trial 57 REVLIMID lenalidomide 57 TOLAMBA 57 VA# [002] 57 desvenlafaxine succinate 57 Iluvien ® 57 ProLindac 57 Cinquil 57 multicentre study 57 Vitaxin 56 Prestara 56 forodesine HCl 56 ALN RSV# 56 Ceplene R 56 cathepsin K inhibitor 56 fenretinide 56 DB# [003] 56 QNEXA 56 PrevOnco 56 hypoxia activated prodrug 56 recurrent glioblastoma multiforme 56 Elagolix 56 Kamada AAT 56 BLOOM DM 56 Loramyc ® 56 L BLP# 56 Virulizin R 56 ILUVIEN ® 56 non alcoholic steatohepatitis 56 initiate Phase 2a 56 Phase 2b Clinical Trial 56 Feasibility Trial 56 dasatinib Sprycel ® 56 TORISEL 56 bevacizumab Avastin 56 Cethrin 56 pralatrexate injection 56 kinase inhibitor 56 metastatic CRPC 56 Myocet 56 investigational antiplatelet agent 56 Zenvia TM 56 SPIRIT FIRST 56 AVE# 56 ZYBRESTAT fosbretabulin 56 ARDIS 56 myelofibrosis 56 KNS # 56 metastatic castration resistant 56 LE SN# 56 glatiramer acetate 56 multicenter trials 56 RSD# 56 Riquent 56 Phase IIA 56 DAPT 56 inhaled formulation 56 custirsen 56 nucleotide analog 56 Marketing Authorisation Application 56 XL# [003] 56 NCCTG 56 XmAb# 56 rilonacept 56 Clinical Antipsychotic Trials 56 Panzem R 56 Leukine 56 Entereg 56 carboplatin paclitaxel 56 interferon beta 1b 56 ATHX 56 afamelanotide 56 Plenaxis R 56 FAME Study 56 danoprevir 56 randomized controlled trial 56 investigational protease inhibitor 56 Alpharadin 56 ENDEAVOR III 56 anticancer compound 56 taranabant 56 Nasdaq PGNX today 56 trodusquemine 56 ROCKET AF 56 EVIZON 56 hepatitis C HCV 56 synthetic retinoid 56 INTERCEPT platelets 56 urocortin 2 56 ORENCIA R 56 Gattex 56 HoFH 56 velafermin belinostat 56 Clavis Pharma 56 LymphoStat B belimumab 56 atacicept 56 Sigma Tau SpA 56 RhuDex TM 56 DEB# 56 FOSRENOL 56 Vicriviroc 56 Preos 56 RRMS patients 56 afatinib 56 picoplatin 56 PEP# [003] 56 ospemifene 56 evaluating REVLIMID 56 tamibarotene 56 vemurafenib 56 GEM OS1 56 randomized multicenter trial 56 TroVax 56 AIMM trial 56 fosbretabulin 56 PRESEPT 56 SPIRIT III 56 metastatic RCC 56 mGluR5 negative 56 Degarelix 56 anidulafungin 56 LY# [003] 56 mixed dyslipidemia 56 VitiGam 56 Parkinson disease levodopa induced 56 ORENCIA ® 56 Clinical Trial 56 Tezampanel 56 pseudobulbar affect PBA 56 Proellex TM 56 omacetaxine 56 JZP 56 MYDICAR 56 Ofatumumab 56 clinicaltrials 56 HER2 positive metastatic breast 56 satraplatin 56 Blinatumomab 56 lumiliximab 56 ascending doses 56 Pirfenidone 56 OncoGel 56 TRIOLEX 56 personalized immunotherapy 56 platinum refractory 56 Stimuvax 56 tocilizumab 56 FIRMAGON R 56 motesanib 56 Velcade bortezomib 56 Tesetaxel 56 Initiated Phase 56 Itopride 56 mGluR2 positive 56 retigabine 56 OHR/AVR# 56 Nasdaq HALO 56 ZOLINZA 56 BST CarGel R 56 rilpivirine 56 Dose escalation 56 Anturol TM 56 Zoraxel 56 Daclizumab 56 Taxotere ® 56 randomized 56 cardio renal 56 Inhalation Solution 56 ENESTnd 56 Soliris TM eculizumab 56 COSIRA trial 56 PA# [002] 56 Amigal TM 56 satraplatin Phase 56 NXL# 56 Vascular Wrap TM 56 MORAb 56 Darusentan 56 tesetaxel 56 Enobia 56 RE SURGE 56 MIVI III 56 radiation sensitizer 56 apaziquone 56 AVN# [001] 56 Dose Ranging Study 56 adipiplon 56 NLX P# 56 BYDUREON 56 CytoFabTM 56 docetaxel chemotherapy 56 PMA submission 56 LCP Tacro 56 mapatumumab 56 blind multicenter 56 StemEx 56 AEZS 56 tramiprosate Alzhemed TM 56 humanized monoclonal antibody 56 Multiple Ascending Dose 56 Carfilzomib 56 PDX pralatrexate 56 IPX# 56 refractory multiple myeloma 56 bile duct tumor

Back to home page